γ-Aminobutyric acid (GABA), the main inhibitory neurotransmitter in the vertebrate brain, acts on ionotropic (GABA A or GABA C ) and metabotropic (GABA B ) receptors. Ionotropic GABA receptors are ligand-gated chloride channels that mediate fast GABA response, whereas metabotropic GABA B receptors, belonging to the C family of G-protein-coupled receptors (GPCRs), mediate slow GABA response by activating G-proteins and their downstream effectors (Pinard et al. 2010) . GABA B receptors were discovered in the mammalian central nervous system by Bowery and colleagues (1980) and cloned by Bettler's research team (Kaupmann et al. 1997 ) with similarity to other metabotropic receptors in sequence. Being distributed in most regions of the brain, GABA B receptors have been implicated in a variety of neurological and psychiatric disorders, including epilepsy, spasticity, schizophrenia, anxiety, depression, cognitive impairment, and drug abuse (Bettler et al. 2004; Filip and Frankowska 2008) . GABA subunits, which are encoded by two different genes (Kaupmann et al. 1997; Jones et al. 1998; Kaupmann, Malitschek, et al. 1998; White et al. 1998; Ng et al. 1999) . Both subunits contain a large extracellular N-terminal domain, seven-transmembrane domains, and a short intracellular C-terminal domain. Importantly, the C-terminal domains of both subunits contain a coiled-coil structure involved in the heterodimerization of GABA B receptors (Kaupmann, Malitschek, et al. 1998; Bettler et al. 2004; Benke 2010) (Fig. 1) .
Despite their similar three-dimensional structures, GABA B1 and GABA B2 subunits have different ligand-binding capabilities, G-protein coupling, and cell surface trafficking (Fig. 1) . First, the extracellular domain of GABA B1 is capable of binding endogenous neurotransmitter (i.e., GABA), agonists (i.e., baclofen), and antagonists (i.e., CGP54626 or CGP54626) (Kaupmann et al. 1997; Filip and Frankowska 2008) . The extracellular domain of GABA B2 has no ligand-binding activity, whereas the transmembrane domain of GABA B2 can bind allosteric modulators (i.e., CGP7930), which have no intrinsic activity but modulate the affinity of the ligand for GABA B1 and signal transduction efficacy following ligand binding (Kaupmann, Malitschek, et al. 1998; Galvez et al. 2001; Kniazeff et al. 2002; Urwyler et al. 2005; Filip and Frankowska 2008) . Second, the intracellular domain of GABA
B2
but not GABA B1 is coupled to G-proteins and regulates the activities of the Ca 2+ channel, K + channel, adenylyl cyclase (AC), or phospholipase C (PLC) (Galvez et al. 2001; Margeta-Mitrovic et al. 2001; Duthey et al. 2002; Havlickova et al. 2002; Bettler et al. 2004 ). Third, GABA B1 is prevented from reaching the cell surface due to an endoplasmic reticulum (ER) retention signal (RSRR) in its intracellular tail. However, the coiled-coil interaction between C-terminal tails of GABA B1 and GABA B2 subunits can mask the ER retention signal, resulting in cell surface trafficking of heterodimeric GABA B receptors Margeta-Mitrovic et al. 2001; Pagano et al. 2001) (Prosser et al. 2001; Schuler et al. 2001; Gassmann et al. 2004) .
Recent studies have been revealed that heterodimeric GABA B receptors can form higher-ordered oligomers. Using snap-tag technology to specifically label cell surface GABA (Fig. 2) . The C-termini of GABA B receptors interact with a variety of proteins, including transcription factors ATF4 (activating transcription factor 4)/CREB2 (cAMP-responsive element binding protein 2) and CHOP, scaffold proteins 14-3-3, NEM-sensitive factor (NSF) and tamalin, PDZ domain-containing protein MUPP1, and actin-binding protein β-filamin (reviewed in Bettler et al. 2004) . Recently, potassium channel tetramerization domain-containing (KCTD) proteins 12, 12b , and 16 were identified as auxiliary GABA are the only isoforms that are highly conserved in human, rat, mouse, chicken, frog, and zebrafish (Kaupmann et al. 1997; Bettler et al. 2004 ), but they have distinct temporal and spatial expression patterns. GABA B1a protein expression in the brain of the newborn mouse was maintained at a high level until postnatal day 7, after which the expression decreased, with a significantly lower level in the adult brain. By contrast, GABA B1b protein was generally expressed at higher levels in the adult brain compared with the fetal brain. In the cerebellum, GABA B1a mRNAs were predominantly in the granule cell layer, whereas GABA B1b transcripts were mostly expressed in Purkinje cells (Bettler et al. 2004) . Further studies using mice with mutations in the initiation codon of GABA B1a or GABA
B1b
, referred to as GABA B1a -/-or GABA B1b -/-mice, respectively, showed differential compartmentalization and distinct functions of these two isoforms. In the CA1 region of the hippocampus, GABA B1a was predominantly localized at glutamatergic terminals, whereas GABA B1b was mostly localized in dendritic spines. Similar results were obtained from the organotypic hippocampal slice cultures, in which transfected (Martin et al. 2001) . Rat GABA B1(c-a) and GABA B1(c-b) are similar to GABA B1a and GABA
, respectively, except that the former two contain an in-frame insertion of 93 bp between exons 4 and 5 (light blue box) (Isomoto et al. 1998) . GABA B1d has no SDs at the N-terminus, but it contains an insertion of 566 bp at the 3′-end, resulting in a divergent C-terminus with half of the coiled-coil domain being deleted and the loss of the ER retention signal (light orange box) (Isomoto et al. 1998) . Due to the skipping of exon 15, GABA B1e encodes the extracellular ligand binding domain with a C-terminal truncation (only 9 amino acid residues of the transmembrane domain are retained; indicated by the dark blue box) (Schwarz et al. 2000) . GABA B1f contains an in-frame deletion of exon 5, resulting in a 21-bp deletion in the extracellular N-terminal domain and a 93-bp in-frame insertion between exons 4 and 5 (light blue box) (Wei, Eubanks, et al. 2001) . GABA B1g contains exons 1 to 4 followed by 124 bp of intron 4, and the predicted protein is a C-terminal-truncated GABA GABA B1a -green fluorescence protein (GFP) was selectively expressed in distal axons, whereas GABA B1b -GFP was expressed in the majority of dendritic spines, implying that SDs might be responsible for retaining GABA B1a at distal axons. At hippocampal CA3-to-CA1 synapses, GABA B1a heteroreceptors inhibited presynaptic glutamate release, whereas GABA B1b mediated postsynaptic inhibition. Of note, synaptic plasticity and hippocampus-dependent memory were impaired in GABA B1a -/-mice rather than GABA B1b -/-mice, suggesting the functional specialization of GABA B1a and GABA B1b isoforms (Vigot et al. 2006; Pinard et al. 2010 (Isomoto et al. 1998; Pfaff et al. 1999) .
Rat GABA B1d transcript ( Fig. 2) was detected in the forebrain, cerebellum, eye, kidney, and urinary bladder, indicating that the protein may function in peripheral tissues in addition to the central nervous system (CNS) (Isomoto et al. 1998) . GABA B1e transcript (Fig. 2) is a minor component in the CNS of both humans and rats, but it is the primary isoform in a variety of peripheral tissues (Schwarz et al. 2000) . Interestingly, the GABA B1e transcript was detected in human lung epithelial adenocarcinoma cells H441 (Mizuta et al. 2008) . The broad mRNA expression of GABA were identified from rat cDNA library screens (Fig. 2) . GABA B1f and GABA B1g transcripts were prevalently expressed in peripheral tissues (heart, liver, lung, kidney, colon, stomach, spleen, and testis) when compared with brain tissues (Wei, Eubanks, et al. 2001; , whereas GABA B1h and GABA B1i transcripts were widely expressed in the brain and peripheral tissues with variable expression levels (Holter et al. 2005) . GABA B1j transcripts were detected in human, rat, and mouse (Fig. 2) . When compared with GABA B1a , the relative expression level of the GABA B1j transcript was remarkably lower in the human brain than in rat and mouse brains (Tiao et al. 2008; Lee et al. 2010 was not studied (Tiao et al. 2008) . GABA B1k/l/m/n were recently cloned in human and/or mouse (Fig. 2) . It is reported that GABA (Lee et al. 2010) .
In contrast to the molecular diversity of GABA
B1
, there are no confirmed isoforms of GABA B2 so far (Bettler et al. 2004) . Taken together, GABA B1 has multiple isoforms. Of note, there is no direct evidence for the in vivo protein expressions of minor isoforms 1c through 1n. Because isoforms 1e and 1j lacking transmembrane domains are expressed as secreted proteins in heterologous systems, isoforms 1g, 1h, 1i, 1l, and 1m, all of which have C-terminal truncations, may also be expressed as secreted proteins in vivo. Are these proteins able to disrupt the association of GABA B1a /GABA B2 as well as impair the function of GABA B receptors? Based on the ubiquitous mRNA expressions of isoforms 1d through 1i in peripheral tissues, could the transcripts of minor isoforms 1j through 1n also be detected in peripheral tissues? What are the functions of GABA B1 isoforms, particularly the truncated isoforms in the peripheral tissues in vivo? All these questions need to be addressed.
GABA B Receptor Expression in Tumors
A growing body of evidence showed that neurotransmitters have modulatory roles in tumor cells, therefore influencing tumor development and progression. Accordingly, the potential roles of neurotransmitter receptors in tumors have attracted more and more research interest (Schuller 2008) . GABA B receptors have been reported to be involved in tumor development and the proliferation and migration of tumor cells.
GABA B

Receptors and Tumor Development
The expression of GABA B receptors was detected in human hepatocellular carcinoma (HCC) cell lines (HepG2, Bel-7402, Huh-7) and colon cancer cell lines (KM12SM, HT29, RKO) by immunoblotting (Thaker et al. 2005; Wang et al. 2008 ). Importantly, the expression level of GABA B receptors was upregulated in some human tumor tissues when compared with the corresponding normal tissues. Roberts et al. (2009) in human ductal breast cancer (six cases) by immunohistochemistry, and the preliminary data (Fig. 3) showed that GABA B1 expression was significantly higher in malignant 
GABA B Receptors and Tumor Cell Proliferation and Migration
Several studies revealed that activation of GABA B receptors suppresses tumor cell proliferation. Schuller et al. (2008a Schuller et al. ( , 2008b examined the effect of baclofen on the proliferation of human pancreatic ductal adenocarcinoma (PDAC) cells PANC-1 and BXPC-3, human pulmonary adenocarcinoma (PAC) cells NCI-H322, immortalized human pancreatic duct epithelial cells HPDE6-C7, and small airway epithelial cells HPL1D. The β-adrenergic receptor (β-AR) agonist isoproterenol significantly promoted the proliferation of these five cell lines, but baclofen completely abrogated such response. Wang et al. (2008) reported that the proliferation of hepatocarcinoma cells Bel-7402 and Huh-7 was inhibited by baclofen in a dosedependent manner. Systemic administration of baclofen significantly suppressed the growth of Bel-7402 xenograft induced in nude mice. In addition, a remarkable growth inhibition of experimental mammary cancer 16/C was observed in mice treated with baclofen (Opolski et al. 2000) . These observations suggest that GABA B receptor activation inhibits tumor cell proliferation both in vivo and in vitro. However, when human prostate cancer cells LNCaP, MDA-PCA-2b, DU145, and PC-3 were treated with baclofen, no inhibitory effect on BrdU incorporation was observed (Abdul et al. 2008) . GABA B receptor activation also inhibits tumor cell migration. The β-AR agonist norepinephrine strongly increased the migration of human colon carcinoma cells SW480 and breast carcinoma cells MDA-MB-468, but baclofen completely blocked the effect of norepinephrine (Drell et al. 2003; Joseph et al. 2002) . Similarly, the stimulatory effect of isoproterenol on the migration of human PAC cells NCI-H322 and human PDAC cells PANC-1 and BXPC-3 was also abrogated by baclofen (Schuller et al. 2008a (Schuller et al. , 2008b . However, the invasion of C4-2 human prostate cancer cells as well as their expression of matrix metalloproteinase-3 (MMP-3) was significantly enhanced by baclofen but inhibited by GABA B receptor antagonist CGP 35348, suggesting that activated GABA B receptors may increase the invasive ability of tumor cells by promoting MMP-3 production (Azuma et al. 2003) .
Collectively, GABA B receptor activation has inhibitory effects on the proliferation and migration of most human tumor cell types but has no influence on the proliferation of human prostate cancer cells and even promotes the invasion of C4-2 cells. The underlying mechanism remains unclear. It is possible that human prostate cancer cells express high levels of soluble GABA B1 isoforms, which compete for baclofen binding with GABA B1a/1b , resulting in different responses to baclofen.
Signaling Events Downstream of GABA B Receptor Activation in Tumor Cells
The classical mitogen-activated protein kinase (MAPK) pathway (Raf/MEK/ERK), activated by cell surface receptor tyrosine kinases (RTKs) following growth factor binding, regulates cell proliferation. Activation of the Raf/ MEK/ERK pathway is a frequent event in different human cancers (Pratilas and Solit 2010) . In human PAC cells NCI-H322 and immortalized human small airway epithelial cells HPL1D, β-AR agonist significantly increased the phosphorylation of ERK1/2 via dual signaling pathways involving the activation of protein kinase A (PKA) and transactivation of epithelial growth factor receptor (EGFR). Such response was completely abrogated by preexposure of the cells to baclofen (Laag et al. 2006; Schuller et al. 2008b ). However, baclofen strongly induced the phosphorylation of ERK1/2 in the CA1 area of the mouse hippocampus as well as in cultured mouse cerebellar granular neurons (CGNs) (Vanhoose et al. 2002; Tu et al. 2007) . The reason for the opposing effects of baclofen on cell proliferation remains unknown but may relate to differential expression of GABA B1 isoforms in neurons and tumor cells. As mentioned previously, transcripts of the C-terminaltruncated GABA B1e and GABA
B1g
were mainly or prevalently expressed in peripheral tissues even in tumor cells (Schwarz et al. 2000; . The expression of these soluble GABA Published data showed that cAMP production in a variety of human cancer cell lines induced by the β-AR agonist was completely blocked by baclofen (Joseph et al. 2002; Schuller et al. 2008a Schuller et al. , 2008b Wang et al. 2008) . Similar results were obtained from rat CGNs, in which cAMP production stimulated by forskolin was reduced by baclofen in a dose-dependent manner (Barthel et al. 1996) . CREB, a classic downstream effector of PKA, was strongly phosphorylated in NCI-H322 and HPL1D cells treated with β-AR agonist, whereas pretreatment of the cells with baclofen completely blocked CREB phosphorylation (Laag et al. 2006; Schuller et al. 2008b) . Again, opposing effects were observed in mouse CGNs; briefly, baclofen induced ERK-dependent CREB phosphorylation (Tu et al. 2007) .
CREB belongs to the ATF/CREB family of transcription factors, which is grouped into several subgroups, including CREB/CREM, CRE-BP1/ATF2, ATF3, ATF4/CREB2, ATF6, and B-ATF subgroups. ATF/CREB family members contain the consensus ATF/CRE binding site and share conserved C-terminal basic leucine zipper domains but vary in their N-termini, which contain phosphorylation sites for PKA, protein kinase C (PKC), or MAPK. Phosphorylation of ATF/CREB family members regulates gene transcription positively or negatively (Karpinski et al. 1992; Hai and Hartman 2001) . ATF4/CREB2, a ubiquitous expressed transcription factor, contains phosphorylation sites for MAPK instead of PKA at the N-terminus (Karpinski et al. 1992 ). Colocalization of ATF4/CREB2 with GABA B receptors has been observed in primary neuron cultures, and the interaction involves the leucine zipper of ATF4/CREB2 and the coiled-coil domain of GABA B1a (Nehring et al. 2000; White et al. 2000; Vernon et al. 2001) . The activation of the GABA B receptor in mouse CGNs may transactivate an RTK, which has been observed in mouse CGNs (Tu et al. 2010) , resulting in MAPK activation and subsequent CREB phosphorylation. The interaction between ATF4/CREB2 and GABA B receptors provides a spatial advantage for the phosphorylation of ATF4/CREB2 by MAPK, which is also recruited to the vicinity of the cell membrane upon RTK activation. It would be interesting to know whether disrupting the interaction between ATF4/CREB2 and GABA B receptors will suppress the stimulatory effect of baclofen on CREB phosphorylation in CGNs. Compared with ATF4/ CREB2 in CGNs, the ATF/CREB family members expressed in tumor cells may contain phosphorylation sites for PKA, which are inactivated by the decreased cAMP level triggered by baclofen, leading to reduced phosphorylation of CREB. Identification of the predominant ATF/ CREB family member(s) expressed in different tumor cell types will help researchers understand the mechanism regulating ATF/CREB phosphorylation by GABA B receptors.
The phosphoinositide 3-kinase (PI3K) pathway regulates cell growth, survival, metabolism, and motility, and it is frequently activated in a variety of human cancers (Courtney et al. 2010; Wong et al. 2010) . Currently, no published data show the activation of the PI3K pathway by the GABA B receptor agonist in tumor cells, but a recent report revealed that activation of GABA B receptors by baclofen in mouse CGNs transactivated insulin-like growth factor 1 receptor (IGF-1R), leading to Akt activation and protection of neurons from apoptosis (Tu et al. 2010) . Probably, the PI3K pathway is also regulated by GABA B receptors in tumor cells, which results in altered cell proliferation and migration.
As described above, the expression of GABA 
Conclusions
Heterodimeric GABA B receptors may exist as a large complex due to oligomerization and association with a variety of other proteins, mainly through the C-termini of both subunits. 
